David Maloney, MD, PhD

No bio available.

Financial relationships

  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Juno therapeutics
    Topic:
    Research funding paid to my institution
    Date added:
    04/25/2023
    Date updated:
    04/25/2023
    Relationship end date:
    12/31/2030
  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Celgene
    Topic:
    Research funding paid to my institution
    Date added:
    04/25/2023
    Date updated:
    04/25/2023
    Relationship end date:
    12/31/2030
  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Legend Biotech
    Topic:
    Research funding paid to my institution
    Date added:
    04/25/2023
    Date updated:
    04/25/2023
    Relationship end date:
    12/31/2024
  • Attribution:
    Other
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Bristol-Myers Squibb
    Topic:
    Research funding paid to my institution
    Date added:
    04/25/2023
    Date updated:
    04/25/2023
    Relationship end date:
    12/31/2030
  • Attribution:
    Self
    Type of financial relationship:
    Patent
    Ineligible company:
    Juno Therapeutics/BMS
    Topic:
    Dr. Maloney has the rights to royalties from Fred Hutch for patents licensed to Juno Therapeutics/BMS
    Date added:
    04/25/2023
    Date updated:
    04/25/2023
    Relationship end date:
    07/02/2024
  • Attribution:
    Self
    Type of financial relationship:
    Stock Options
    Ineligible company:
    A2 Biotherapeutics
    Topic:
    Member, Scientific Advisory Board
    Date added:
    04/25/2023
    Date updated:
    04/25/2023
    Relationship end date:
    12/30/2030
  • Attribution:
    Self
    Type of financial relationship:
    Stock Options
    Ineligible company:
    Navan Technologies
    Topic:
    Member, Scientific Advisory Board
    Date added:
    04/25/2023
    Date updated:
    04/25/2023
    Relationship end date:
    12/30/2030
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Chimeric Therapeutics
    Topic:
    Member, Scientific Advisory Board
    Date added:
    04/25/2023
    Date updated:
    04/25/2023
    Relationship end date:
    12/30/2030
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Genentech
    Topic:
    Member and Chair, Lypmphopma Steering Committee
    Date added:
    04/25/2023
    Date updated:
    04/25/2023
    Relationship end date:
    12/30/2030
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    BMS
    Topic:
    Member, JCAR017 EAP-001 Safety Review Committee and the CLL Strategic Council
    Date added:
    04/25/2023
    Date updated:
    04/25/2023
    Relationship end date:
    12/30/2030

Pages

Return to Seattle Cellular Therapy Summit: Patient-Centered Approach to Improve Outcomes